Taiwanese Upstart Emerges As Threat To Biovail's Wellbutrin XL Patent

Law360, New York (November 17, 2004, 12:00 AM EST) -- Canadian drug maker Biovail Corp. is bracing itself for a legal battle against upstart Taiwanese drug maker Anchen Pharmaceuticals Inc. over patent rights to blockbuster once-daily antidepressant Wellbutrin XL.

Earlier this week, Biovail said Anchen had submitted an abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) for the drug, known generically as bupropion.

Two other generics manufacturers, Eon and Impax, have indicated they intend to file similar ANDAs in the near future.

Closely held Anchen was formed two years ago by...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.